Form 4: Quest Diagnostics Director Defers Compensation
Insider Transaction Report
A Quest Diagnostics director acquired phantom stock units through an elective deferral of cash compensation.
Summary
- Wright L. Lassiter, III, a Director at Quest Diagnostics Inc. (DGX), acquired 157 phantom stock units on October 1, 2025.
- These units resulted from an elective deferral of the director's cash compensation under the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors.
- The phantom stock units are payable in cash upon the reporting person's termination of service as a director.
- The total number of phantom stock units beneficially owned by Mr. Lassiter following this transaction is 678.777.
- This total includes phantom stock units credited from dividend reinvestment transactions, which are exempt from reporting under Rule 16a-11.
Sentiment
Score: 5
Explanation: The filing is neutral as it reports a routine, non-market transaction related to director compensation, which is neither inherently positive nor negative for the company's operational or financial performance.
Positives
- Director Wright L. Lassiter, III, is increasing his beneficial ownership in Quest Diagnostics through deferred compensation, aligning his interests with shareholders.
- The deferral mechanism indicates a structured compensation plan for directors.
Future Outlook
The phantom stock units become payable in cash upon the reporting person's termination of service as a director.
Industry Context
This is a routine insider transaction related to director compensation, common across publicly traded companies, and does not reflect broader industry trends or competitive positioning.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Reference | The transaction occurred pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors. | 10/01/2025 | This highlights the existing framework for director compensation and deferral options, aligning director interests with long-term company performance. |
Related Party Transactions
- The acquisition of phantom stock units by Director Wright L. Lassiter, III, is a transaction between a director and the company, structured under a pre-existing deferred compensation plan.
Stakeholder Impact
- Shareholders: The transaction aligns the director's long-term interests with the company's performance through deferred compensation.
- Employees: No direct impact on general employees is indicated.
- Management: Reflects standard compensation practices for directors.
Next Steps
- Phantom stock units will become payable in cash upon the reporting person's termination of service as a director.
Key Dates
| Date | Description |
|---|---|
| 10/01/2025 | Date of transaction where phantom stock units were acquired. |
| 10/03/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Quest Diagnostics, DGX, Form 4, Insider Transaction, Phantom Stock Units, Deferred Compensation, Director Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.